Cargando…

Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still the main therapeutic approach for this subgroup of patients, therefore, progress in the treatment of TNBC remains an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cocco, Stefania, Piezzo, Michela, Calabrese, Alessandra, Cianniello, Daniela, Caputo, Roberta, Di Lauro, Vincenzo, Fusco, Giuseppina, di Gioia, Germira, Licenziato, Marina, de Laurentiis, Michelino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369987/ https://www.ncbi.nlm.nih.gov/pubmed/32605126 http://dx.doi.org/10.3390/ijms21134579

Ejemplares similares

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

Targeting Autophagy in Breast Cancer
por: Cocco, Stefania, et al.
Publicado: (2020)

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
por: Piezzo, Michela, et al.
Publicado: (2020)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
por: Piezzo, Michela, et al.
Publicado: (2021)

Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models
por: Cocco, Stefania, et al.
Publicado: (2022)

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
por: Botti, Gerardo, et al.
Publicado: (2017)

NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
por: Caputo, Roberta, et al.
Publicado: (2023)

Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer
por: Collina, Francesca, et al.
Publicado: (2015)

A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results
por: Cozzolino, Mauro, et al.
Publicado: (2021)

LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer
por: Collina, Francesca, et al.
Publicado: (2019)

Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology
por: Amirkhani Namagerdi, Asadoor, et al.
Publicado: (2020)

Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5
por: D’Esposito, Vittoria, et al.
Publicado: (2016)

Rare tumours of the breast
por: Esposito, Emanuela, et al.
Publicado: (2019)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness
por: di Gennaro, Alessandra, et al.
Publicado: (2018)

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
por: Caputo, Roberta, et al.
Publicado: (2020)

Long Non-Coding RNA HOTAIR in Breast Cancer Therapy
por: Cantile, Monica, et al.
Publicado: (2020)

Male Breast Cancer: From Molecular Genetics to Clinical Management
por: Pensabene, Matilde, et al.
Publicado: (2022)

Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
por: Brito Baleeiro, Renato, et al.
Publicado: (2023)

Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives
por: Oualla, Karima, et al.
Publicado: (2020)

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
por: Di Mauro, Concetta, et al.
Publicado: (2017)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)

Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement
por: Adamo, Vincenzo, et al.
Publicado: (2022)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni, Antonio, et al.
Publicado: (2016)

Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Vici, Patrizia, et al.
Publicado: (2016)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Blockchain as enabling factor for implementing RFID and IoT technologies in VMI: a simulation on the Parmigiano Reggiano supply chain
por: Cammarano, Antonello, et al.
Publicado: (2022)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
por: Pelizzari, Giacomo, et al.
Publicado: (2018)

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Triple-negative Breast Cancer Arising in a Fibroadenoma in BRCA 1 Mutated Patient
por: Brunetti, Nicole, et al.
Publicado: (2022)

Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis
por: Vici, Patrizia, et al.
Publicado: (2015)

Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies
por: Berretta, Massimiliano, et al.
Publicado: (2020)

Animal Models of CMT2A: State-of-art and Therapeutic Implications
por: De Gioia, Roberta, et al.
Publicado: (2020)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
por: D’Arienzo, Andrea, et al.
Publicado: (2023)

T-cadherin is associated with prognosis in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2017)

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
por: De Angelis, Carmine, et al.
Publicado: (2017)

Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
por: De Laurentiis, Michelino, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0v1m2h1p6qbebfqdp2kckchta6